HilleVax Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from HilleVax Inc
Access all reports
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company’s primary product under development is HIL-214, a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax has been working on advancing this vaccine through clinical trials, with efforts to evaluate its safety and efficacy across different age groups. Hillevax is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for HilleVax Inc
Corporate Presentation
HilleVax Inc
Corporate Presentation
HilleVax Inc
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
HLVX
Country
🇺🇸 United States